Reuben Gregg Brewer, The Motley Fool
5 min read
Johnson & Johnson (NYSE: JNJ) is a member of the highly elite club of companies known as Dividend Kings. It has increased its dividend annually for a huge 64 years. As you consider the $7 billion charge the company took in the third quarter of 2026, which pummeled its earnings, keep in mind its incredible dividend track record. This is a business that knows how to survive and thrive.
In fact, despite the weak quarterly earnings, J&J upped its full-year guidance. Here’s a deep dive into what happened and what it means for conservative long-term dividend investors.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
What’s up with J&J’s $7 billion charge?
To quote the company, “Results in the quarter were impacted by the proposed talc litigation resolution as well as expenses associated with the Firefly Bio transaction and Sail Biomedicines’ collaboration amounting to approximately $7 billion.” There are two pieces to consider here, one not so good and one that’s much better.
The negative is the litigation expense. J&J spun off the business that used to make talcum powder, but it still faces exposure to the class action lawsuit alleging the company’s talcum powder caused cancer. It has a potential settlement that will largely end the litigation, but it comes at a high cost. An initial payment of $3 billion is due in 2027, with the remainder of the proposed $5.5 billion settlement set to be paid in future years. That’s a lot of money, but at least it could help bring to a close a legal headwind that has dogged the company for years.
Meanwhile, the remainder of the quarterly charge was for items that will help J&J grow over the long term: an acquisition and a partnership. Simply put, despite the legal distractions this healthcare giant faces, it remains focused on long-term growth.
The big-picture story is still good for J&J
What’s interesting is that J&J increased its full-year revenue and earnings guidance even as it took that big quarterly charge. It highlights something that the company’s status as a Dividend King hints at: J&J knows how to thrive through good times and bad.
Even the best-run businesses eventually go through difficult periods. Surviving those periods while continuing to reward investors with regular dividend increases is a distinction that sets J&J apart. In fact, it has the longest dividend streak of any healthcare company.
